{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:48:29Z","timestamp":1774367309326,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bmcl.2024.129911","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:10:07Z","timestamp":1722003007000},"page":"129911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of aminopiperidine based potent &amp; novel topoisomerase inhibitor with broad spectrum anti-bacterial activity"],"prefix":"10.1016","volume":"111","author":[{"given":"Jigar","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaumin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandini","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Gite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brijesh","family":"Darji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasinath","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinal","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purvi","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwanath","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachchidanand","family":"S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129911_b0005","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/432803","article-title":"Overview of nosocomial infections caused by Gram-negative Bacilli","volume":"41","author":"Weinstein","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2024.129911_b0010","unstructured":"WHO antimicrobial resistance Global Report on Surveillance. WHO Geneva, 2014. https:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en."},{"key":"10.1016\/j.bmcl.2024.129911_b0015","unstructured":"Centers for Disease Control and Prevention, Antibiotic Antimicrobial Resistance, Centers for Disease Control and Prevention, Atlanta, 2017. https:\/\/www.cdc.gov\/drugresistance\/index.html."},{"key":"10.1016\/j.bmcl.2024.129911_b0020","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmcl.2024.129911_b0025","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1128\/AAC.01103-16","article-title":"Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States","volume":"60","author":"McGann","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2024.129911_b0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmcl.2024.129911_b0035","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.129911_b0040","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/AAC.00496-08","volume":"52","author":"Black","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2024.129911_b0045","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1021\/acs.jmedchem.9b01738","article-title":"Two decades of successful SAR-grounded stories of the novel bacterial topoisomerase inhibitors (NBTIs)","volume":"63","author":"Kolaric","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129911_b0050","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/jm501590q","article-title":"Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-Gram positive activity and improved safety profile","volume":"58","author":"Surivet","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129911_b0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/ijms19020453","article-title":"Novel bacterial topoisomerase inhibitors exploit Asp83 and the intrinsic flexibility of the DNA gyrase binding site","volume":"19","author":"Ulloa","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2024.129911_b0060","first-page":"1000017","article-title":"Novel Bacterial Topoisomerase inhibitors (NBTIs) \u2013 A comprehensive review","volume":"3","author":"Desai","year":"2021","journal-title":"Eur. J. Med. Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129911_b0065","unstructured":"Janelle CP, Mark C, Bolin G, Ayden GA, Folkert R, WIPO patent, WO2008071961, 2008."},{"key":"10.1016\/j.bmcl.2024.129911_b0070","unstructured":"David DD, Elgi JG, Edward MWR, William M, David PN, WIPO patent, WO2002056882, 2002."},{"key":"10.1016\/j.bmcl.2024.129911_b0075","unstructured":"Chandrasekher A, Ankita B, Radha R, Rajinder K, WIPO patent, WO2004057415, 2004."},{"key":"10.1016\/j.bmcl.2024.129911_b0080","unstructured":"https:\/\/www.gsk.com\/en-gb\/innovation\/pipeline\/?infectious-diseases, Jan 2024."},{"key":"10.1016\/j.bmcl.2024.129911_b0085","unstructured":"Payne D, Rittenhouse, Scangarella-Oman, Gepotidacin for the use in the treatment of bacterial urinary tract infection, WIPO patent, WO 2020201833, 2020."},{"key":"10.1016\/j.bmcl.2024.129911_b0090","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejmech.2018.11.017","article-title":"Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review","volume":"162","author":"Zhao","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129911_b0095","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acs.oprd.0c00029","article-title":"Development of a convergent, kilogram scale synthesis of an antibacterial clinical candidate using an enantioselective hydrogenation","volume":"24","author":"Benson","year":"2020","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.bmcl.2024.129911_b0100","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm300690s","article-title":"Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pKa: antibacterial agents with an improved safety profile","volume":"55","author":"Reck","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129911_b0105","unstructured":"Sharma R, Iyer P, Desai J, Kumar S, Heterocyclic compounds useful as antibacterial agents, wipo patent WO2014057415, 2014."},{"key":"10.1016\/j.bmcl.2024.129911_b0110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cpdd.913","article-title":"Pharmacokinetics of gepotidacin in subjects with normal hepatic function and hepatic impairment","volume":"10","author":"Hossain","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bmcl.2024.129911_b0115","doi-asserted-by":"crossref","first-page":"e00468","DOI":"10.1128\/AAC.00468-17","article-title":"Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria","volume":"61","author":"Flamm","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T22:34:22Z","timestamp":1723502062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24003135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":23,"alternative-id":["S0960894X24003135"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129911","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129911"}}